What Dewpoint Therapeutics does

Dewpoint Therapeutics is a clinical-stage biotechnology company pioneering the application of biomolecular condensate biology to drug discovery. Founded in 2019 by Anthony Hyman (2022 Breakthrough Prize in Life Sciences), Richard Young (Whitehead Institute/MIT), and Phillip Sharp (1993 Nobel laureate, MIT), the company develops a new therapeutic modality called condensate-modulating drugs (c-mods) that correct aberrant condensates ("condensatopathies") underlying complex diseases. Operations span three sites: headquarters and labs in Boston (451 D Street), plus research operations in Dresden and Frankfurt, Germany, the latter co-located with co-founder Hyman's Max Planck Institute. Headcount is approximately 51–120 staff across the network. Targeted indications span oncology (gastric cancer, MYC-driven cancers), neurodegeneration (ALS, FTD), cardiopulmonary disease, metabolic disease, and virology (HPV).

The company's central technical asset is its proprietary AI-powered integrated drug discovery platform, ERSA (powered by the ERSAi engine), which combines nearly 3 petabytes of proprietary data, over 4 million condensate cell images, and a high-throughput condensate phenomics screening system with computer vision to identify c-mod candidates. The platform fuses multimodal data — condensate proteomics, genetics, and cellular phenotypic signatures — through in-house ERSA Computational Models that predict chemical perturbations and functional cellular outcomes. A proprietary condensate-focused compound library and selective-partitioning chemistry support lead optimization. The clinical-stage pipeline includes DPTX3186, a first-in-class oral c-mod targeting the oncogenic Wnt/β-catenin pathway (FDA Orphan Drug and Fast Track Designations, IND opened October 2025, first patient dosed February 2026), alongside preclinical development candidates for MYC-driven oncology and TDP-43 pathology in ALS.

Dewpoint operates a partner-centric business model in which it develops proprietary c-mods internally through Phase 1/2 trials while co-developing assets with major pharmaceutical companies — Bayer (cardiopulmonary), Novo Nordisk (metabolic), Mitsubishi Tanabe Pharma — leveraging their development and commercial capabilities. Anticipated future revenue derives from direct product sales, milestone payments, and royalties on licensed programs; near-term cash flow is supported by collaboration economics and equity capital rather than product revenue. To date the company has raised approximately $367 million across Series A through D equity rounds, with key institutional backers including SoftBank Vision Fund 2 (Series C lead), Polaris Partners, ARCH Venture Partners, Leaps by Bayer, and Samsara BioCapital, plus non-dilutive grant funding from the Bill & Melinda Gates Foundation for its HPV Viral Condensate Phenomics Atlas initiative.

Name

Dewpoint Therapeutics

Legal name

Dewpoint Therapeutics, Inc.

Website

https://dewpointx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Dewpoint Therapeutics is a clinical-stage biotech developing condensate-modulating drugs (c-mods) that target previously undruggable disease biology. Its AI-powered ERSA platform addresses oncology, neurodegeneration, and metabolic diseases, with partnerships spanning Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Condensate-modulating drugs
• Biomolecular condensate biology
• Drug discovery platform
• AI-powered therapeutics
• Clinical-stage biotechnology

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Therapeutic Development & Licensing: Developing proprietary c-mod therapeutics through clinical development with intent to commercialize directly or through licensing partnerships with pharmaceutical companies. Revenue will come from product sales and/or milestone/royalty payments from partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Dewpoint Therapeutics is a clinical-stage biotechnology company developing condensate-modulating drugs (c-mods), a novel class of small-molecule therapeutics that target dysregulated biomolecular condensates to treat complex diseases. The company combines its proprietary AI-powered ERSA drug discovery platform with high-throughput condensate phenomics to discover and develop drug candidates against previously undruggable targets such as MYC and β-catenin in oncology and TDP-43 in neurodegeneration.

Product overview

Dewpoint Therapeutics is pioneering condensate biology to develop a new class of medicines called condensate-modulating drugs (c-mods). The company's integrated platform combines proprietary AI technology (ERSA/ERSAi) with high-throughput condensate phenomics for target identification and drug discovery. The core pipeline includes DPTX3186 (Wnt/β-catenin modulator for gastric cancer in clinical trials), MYC condensate modulator (oncology), and TDP-43 condensate modulator (ALS/neurodegeneration). Dewpoint also develops research tools including the CD-CODE condensate database and viral condensate phenomics atlas, while maintaining strategic partnerships with Bayer, Novo Nordisk, and Chemify.

Differentiator

Problem solved

Functional benefit

Products and services

• DPTX3186 First-in-class oral condensate modulator (c-mod) targeting the oncogenic Wnt/β-catenin pathway for the treatment of gastric cancer and other Wnt-driven solid tumors. Received FDA Orphan Drug Designation (October 2025) and FDA Fast Track designation (November 2025), with IND opened (October 2025) and first patient dosed in the Phase 1a/2a trial in February 2026.
• MYC Condensate Modulator First-in-class small-molecule condensate modulator targeting MYC-driven oncogenic transcription in cancer cells. Development candidate selected in February 2026 with preclinical data demonstrating potency and selectivity in MYC-dependent cellular systems, favorable in vivo pharmacology including tumor regressions in MYC-dependent models, and tolerability supportive of IND-enabling studies.
• TDP-43 Condensate Modulator Small-molecule condensate-modulating drug (c-mod) targeting TDP-43 condensatopathy for the treatment of ALS and related neurodegenerative diseases, including FTD, Perry Syndrome, CTE, and Inclusion Body Myositis. Development candidate nominated in January 2026.
• Condensate-Modulating Drugs (c-mods) Novel therapeutic modality in which small molecules modulate the formation, composition, or dissolution of biomolecular condensates to treat condensatopathies. C-mods can target previously undruggable proteins and pathways by targeting the condensate environment rather than individual protein active sites.

Quantifiable outcome

• DPTX3186 demonstrated tumor regressions in MYC-dependent models and favorable in vivo pharmacology
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• BayercoreStrategic or Co-development PartnerStrategic collaboration for developing condensate-modulating therapeutics in cardiopulmonary diseases. Bayer is a key partner providing pharmaceutical development expertise and resources alongside Dewpoint's condensate biology platform.
• Novo NordiskcoreStrategic or Co-development PartnerStrategic collaboration for developing condensate-modulating therapeutics in metabolic diseases. Novo Nordisk brings global pharmaceutical capabilities and development expertise for metabolic disease programs.
• Mitsubishi Tanabe PharmacoreStrategic or Co-development PartnerCollaboration to advance therapeutic programs leveraging Dewpoint's condensate biology platform in specific disease areas.
• ChemifysupportingTechnology or IntegrationPartnership to develop digitally discovered and automatically synthesized novel molecules against condensate targets in Dewpoint's oncology and neurodegeneration pipeline. Chemify contributes chemistry AI and automation technology platform.
• EvotecsupportingStrategic or Co-development PartnerPartnership through Evotec's INDiGO platform providing integrated preclinical, regulatory, and CMC support for DPTX3186 development candidate to advance into clinical development.
• Max Planck Institute (MPI-CBG)supportingStrategic or Co-development PartnerAcademic partnership with the institute where co-founder Tony Hyman serves as Director and Group Leader. Strong academic ties supporting condensate science research.
• MIT (Massachusetts Institute of Technology)supportingStrategic or Co-development PartnerAcademic partnership with MIT where co-founders Rick Young and Phillip Sharp are faculty members. Partnership supports condensate biology research and talent development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CAMP4 Therapeutics: Closest peer: also founded by Dewpoint co-founder Richard Young, CAMP4 is developing RNA-based therapeutics that target gene regulatory condensates. Directly comparable in modality (condensate biology), stage, and founder network.
• Relay Therapeutics: Clinical-stage precision medicine company using motion-based computational drug discovery (Helix platform) against challenging oncology targets. Comparable as a platform-driven biotech targeting previously undruggable proteins with sophisticated computational approaches.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput phenotypic screening with machine learning. Comparable as a platform biotech using proprietary data, imaging, and AI to power target ID and lead optimization at scale.
• Schrödinger, Inc. Operates a computational drug discovery platform used internally and through partnerships to advance small molecule programs. Comparable as a platform biotech leveraging proprietary physics-based/AI methods to enable drug discovery across pharma partners.
• Insitro: Machine learning-driven drug discovery company combining high-throughput biology with ML models. Comparable as an AI-first platform biotech using proprietary data generation (cellular imaging, omics) and ML for target ID and lead optimization.
• Syros Pharmaceuticals: Gene regulation company co-founded by Dewpoint co-founder Richard Young, focused on controlling expression of disease-driving genes. Comparable in gene-control biology and through shared founder network, though Syros targets transcriptional machinery more directly.

Broad incumbents

• Alnylam Pharmaceuticals: Co-founded by Dewpoint co-founder Phillip Sharp; pioneer in RNAi therapeutics now commercial-stage. Comparable as a long-tenured biotech with shared scientific founder lineage, though it operates in a different therapeutic modality.
• Isomorphic Labs: Alphabet-backed AI drug discovery company with deep resources and pharma partnerships. Comparable as a well-funded AI-first platform biotech operating across multiple therapeutic areas with major pharma partners.

Emerging players

• Genesis Therapeutics: AI-driven drug discovery company using generative models and physics to design small molecules. Comparable as an emerging AI-platform biotech competing for similar pharma partnerships and talent in next-generation computational discovery.
• Atomwise: AI-driven small molecule design company using structure-based deep learning for hit identification across pharma partnerships. Comparable as a smaller AI-platform competitor pursuing similar pharma collaboration economics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/dewpointtx
• LinkedInlinkedin.com/company/dewpointtherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dewpoint Therapeutics